Company Overview
Snapshot
Founded in February 2022 by David C., Benjamin Dekel, Daniel Clayman, and Dorit Omer, RenoVate Therapeutics operates with 1–10 employees. The company has secured funding across one disclosed round from one investor. In March 2022, the company received its initial funding, signaling early investor confidence in its regenerative medicine approach.
Business overview
RenoVate Therapeutics is a Health Tech & Life Sciences company focused on developing regenerative biomolecules to repair and rejuvenate kidneys. The company's core technology involves deriving these biomolecules from cells expanded from a patient's own urine using proprietary methods. Operating within the Pharma & Medical Biotechnology sector, RenoVate Therapeutics serves the healthcare and life sciences markets, targeting providers, patients, and the broader biotechnology industry with its innovative R&D-stage products.
Log in to access full profile ›Company Intelligence Q&A
- What is RenoVate Therapeutics' primary focus?
- RenoVate Therapeutics is dedicated to developing regenerative biomolecules aimed at repairing and rejuvenating kidneys. These biomolecules are derived from cells expanded from the patient’s own urine using proprietary technology.
- When was RenoVate Therapeutics founded?
- RenoVate Therapeutics was founded in February 2022.
- Who are the founders of RenoVate Therapeutics?
- The company was founded by David C., Benjamin Dekel, Daniel Clayman, and Dorit Omer.
- What is the employee count for RenoVate Therapeutics?
- RenoVate Therapeutics currently has 1–10 employees.